MassDevice Q&A: CeQur CEO Jim Peterson
January 21, 2010 by Brad Perriello
CeQur CEO Jim Peterson on his personal ties to diabetes technologies and why his company is poised to be the leader in next-generation insulin delivery devices.
Jim Peterson spent the better part of 20 years helping to improve the quality of the world's blood supply at Haemonetics Corp. (NYSE:HAE), where he was CEO from 1998 to 2003. And while he was passionate about the importance of that work, his new role as chief executive for CeQur Ltd. might be even closer to his heart.
Peterson spoke with MassDevice just before giving a presentation on the patch-like device CeQur is developing for insulin delivery at the OneMedPlace Finance Forum in San Francisco Jan. 13. He told us about the personal connection he feels to his current work, which stems from the fact that his daughter has diabetes, and why he sees Montreux, Switzerland-based CeQur's device as a potential market leader.
Similar entries
Permalink
FDA Database Search
RECENT BLOG POSTS
- Funding R&D: High prices, overuse a failed strategy
- FDA's role in promoting women's health
- New partnership to boost use of GMDN codes for medical devices
- FDA's modern "Corps of Discovery" in China
- Consumers lose in latest FDA user fee bill; COI restraints disappear
- Gamification
- Cool technology of the week
- A new day: Interim thoughts on the 2012 Heart Rhythm Society scientific sessions
- When a child loses milestones, consider sleep EEG studies
- Red or blue pill for payment reform? Both won't work
Features
